Brief: Biohaven Receives FDA May Proceed Letter To Begin Phase 2 Trial Of Intranasal Vazegepant To Treat Lung Inflammation After Covid-19 Infection

PeptiDream

09/04/2020 12:48

April 9 (Reuters) - Biohaven Pharmaceutical Holding Company
Ltd  BHVN.N :
    * BIOHAVEN RECEIVES FDA MAY PROCEED LETTER TO BEGIN PHASE 2
TRIAL
OF INTRANASAL VAZEGEPANT TO TREAT LUNG INFLAMMATION AFTER
COVID-19 INFECTION
    * BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - PHASE 2
STUDY TO
START WITHIN WEEKS, IN COLLABORATION WITH THOMAS JEFFERSON
UNIVERSITY
    * BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - BIOHAVEN
PLANS TO
STUDY INTRANASAL VAZEGEPANT
    * BIOHAVEN PHARMACEUTICAL HOLDING - CLINICAL TRIAL WILL
ASSESS
POTENTIAL BENEFITS OF CGRP RECEPTOR-BLOCKADE IN MITIGATING AN
EXCESSIVE IMMUNE RESPONSE

Source text for Eikon:  ID:nPn4Br8HRa 
Further company coverage:  BHVN.N 

 (Reuters.Briefs@thomsonreuters.com)